VP of Regulatory Affairs of FMD
As a part of the drug evaluation and approval reform in China, the enhanced Marketing Authorization
Holder (MAH) system is now law in China nation-wide. This law eliminates a significant hurdle for drug
developers in registering and marketing an innovative drug in China.